LVW Advisors LLC Makes New $199,000 Investment in Roivant Sciences Ltd. $ROIV

Key Points

• LVW Advisors LLC made a new investment of $199,000 in Roivant Sciences Ltd. by purchasing 17,616 shares in the 2nd quarter.
• Several analysts have recently raised their price targets for Roivant Sciences, with Guggenheim increasing theirs to $21.00 and Goldman Sachs to $24.00, both giving the stock a "buy" rating.
• Insider trading activity included CEO Matthew Gline purchasing 3,315 shares at $15.07 each, while major shareholder Vivek Ramaswamy sold 1,195,000 shares at an average price of $12.50.

LVW Advisors LLC purchased a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 17,616 shares of the company's stock, valued at approximately $199,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Amundi boosted its stake in Roivant Sciences by 18.1% in the 1st quarter. Amundi now owns 398,729 shares of the company's stock worth $3,991,000 after purchasing an additional 61,214 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Roivant Sciences by 16.3% in the first quarter. Bank of New York Mellon Corp now owns 4,000,181 shares of the company's stock valued at $40,362,000 after acquiring an additional 560,641 shares during the period. Inspire Investing LLC purchased a new position in Roivant Sciences during the first quarter valued at approximately $303,000. GAMMA Investing LLC grew its stake in Roivant Sciences by 83.0% during the first quarter. GAMMA Investing LLC now owns 6,493 shares of the company's stock valued at $66,000 after acquiring an additional 2,945 shares in the last quarter. Finally, Peak Financial Advisors LLC bought a new stake in Roivant Sciences during the 2nd quarter worth approximately $472,000. 64.76% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on ROIV shares. Guggenheim lifted their price objective on Roivant Sciences from $15.00 to $21.00 and gave the company a "buy" rating in a research note on Thursday, September 18th. The Goldman Sachs Group lifted their price target on Roivant Sciences from $20.00 to $24.00 and gave the company a "buy" rating in a research report on Thursday, September 18th. Leerink Partners boosted their price objective on Roivant Sciences from $18.00 to $22.00 and gave the stock an "outperform" rating in a report on Thursday, September 18th. Citigroup started coverage on shares of Roivant Sciences in a research note on Tuesday, September 2nd. They issued a "buy" rating and a $16.00 target price on the stock. Finally, Jefferies Financial Group boosted their price target on shares of Roivant Sciences from $18.00 to $20.00 and gave the stock a "buy" rating in a research note on Thursday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $19.94.

Insiders Place Their Bets

In other Roivant Sciences news, CEO Matthew Gline purchased 3,315 shares of the stock in a transaction on Thursday, September 18th. The stock was acquired at an average cost of $15.07 per share, with a total value of $49,957.05. Following the completion of the purchase, the chief executive officer directly owned 17,287,081 shares of the company's stock, valued at approximately $260,516,310.67. This trade represents a 0.02% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Vivek Ramaswamy sold 1,195,000 shares of the company's stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $12.50, for a total transaction of $14,937,500.00. Following the sale, the insider owned 36,089,108 shares of the company's stock, valued at approximately $451,113,850. The trade was a 3.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 3,686,749 shares of company stock valued at $50,302,987. 10.80% of the stock is currently owned by corporate insiders.

Roivant Sciences Trading Up 1.4%

Shares of NASDAQ ROIV opened at $15.17 on Monday. The stock's 50-day moving average is $12.55 and its 200 day moving average is $11.44. The stock has a market cap of $10.36 billion, a price-to-earnings ratio of -21.67 and a beta of 1.15. Roivant Sciences Ltd. has a 1-year low of $8.73 and a 1-year high of $16.05.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

Want to see what other hedge funds are holding ROIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.